https://www.thestar.com.my/business/business-news/2024/07/23/improving-tourist-arrivals-a-boon-for-gaming-sector

Improving tourist arrivals a boon for gaming sector
PETALING JAYA: The gaming sector is poised for a robust recovery in the second half of 2024 (2H24), driven by increased tourist arrivals and regulatory developments, says Hong Leong Investment Bank Research (HLIB Research).

Maintaining an “overweight” stance on the sector, HLIB Research highlighted several key factors supporting the optimistic outlook.

For casino operators, the research house said the recovery trajectory will be sustainable, underpinned by the restoration of global flight capacity and the visa-free-travel pact between China and both Malaysia and Singapore.

“We anticipate continued earnings recovery for Genting Singapore Ltd and Genting Malaysia Bhd in 2H24 and beyond – and thus benefiting Genting Bhd – driven by the ongoing rebound in tourist numbers,” it noted.

Genting owns 52.7% of Genting Singapore and 49.5% of Genting Malaysia.
While Malaysia and Singapore had shown resilience as destinations for Chinese travellers in 2023, HLIB Research pointed out that travel volumes are still at 48% and 47% of 2019 levels, respectively, indicating further potential for recovery.

Malaysia aims to achieve foreign-tourist arrivals of 27.3 million in 2024 versus 20.1 million in 2023 and 26.1million in 2019, while Singapore is hoping to see about 15 to 16 million visitors this year against 13.6 million in 2023 and 19.1 million in 2019.
Specifically, Resorts World Genting and Resorts World Sentosa are poised to benefit from the recovery of Chinese tourist arrivals, a crucial client segment for the gaming industry,” it added.

In addition to the tourism boost, HLIB Research said Genting’s 20.4%-owned associate TauRx Pharmaceuticals Ltd, has shown promising results in its clinical trials for hydromethylthionine mesylate (HMTM), a drug aimed at treating Alzheimer’s disease.

“The new data show that benefit can be maintained over 24 months and highlight the importance of starting HMTM treatment early in the disease process,” said TauRx chief executive officer Claude Wischik earlier this year.

According to HLIB Research, the market for drugs that slow Alzheimer’s progression was devoid of competitors back in 2015.

It said the US Food and Drug Administration (FDA) had recently approved two drugs for treating Alzheimer’s – Leqembi by Biogen and Eisai in July 2023, and Kisunla by company Eli Lilly in July 2024.

With potential FDA approval, TauRx could significantly enhance Genting’s value.
Assuming three of the drugs capture the addressable market equally, this could imply TauRx is worth US$5bil.

“Genting’s stake could be worth US$1bil or RM1.22 per share, which is approximately 25% of current market cap. To be conservative, we will only consider this valuation in our target price post-FDA approval,” it added.

As for number forecast operators (NFOs), HLIB Research pointed to the recent High Court ruling that the Kedah government’s decision to cease issuing and renewing business licences for gaming operators is unconstitutional, as only the federal government has the authority to enact laws and regulations regarding gambling.

To me now is collection mode.. Bought 4.71

let the weak holder sell first. I believe afternoon will comeback even stronger.

AngTayKor......noted with thanks

https://www.thestar.com.my/business/business-news/2024/07/19/genting-plantations-to-acquire-152-hectares-in-indonesia-for-rm593mil-for-property-development

Genting Plantations to acquire 152 hectares in Indonesia for RM593mil for property development

RM5 coming soon.

Once UK approved. Commonwealth country can start selling. China and India may follow.

Waiting for more good news.

OTB - US cannot get. But UK possible.

TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM) for treatment of mild cognitive impairment (MCI-AD) and mild to moderate stages of dementia due to Alzheimer’s disease.

HMTM has been designated by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the Innovative Licensing and Access Pathway (ILAP). If successful, the UK could be the first country in which an accessible, safe, oral treatment, which targets the hallmark tau pathology of the disease, becomes available to patients.

looking good. Keep it up.

The future is very bright.
Just hold on to your shares.

Well. Different person different opinions. Tomorrow will know. Game not over yet. TauRX results could be earlier.

I hope this round could break RM5 before TauRX year end approval.

https://www.thestar.com.my/business/business-news/2024/07/16/gentings-earnings-recovery-a-win

“We understand that TauRx ought to receive a reply by year end.

“Based on our estimates, if HMTM is approved and TauRx is valued at US$15bil, our SOP-based target price (TP) for Genting could be raised to RM9.35,” it noted.

In light of more favourable conditions, Maybank IB Research said it will maintain its “buy” call on Genting with a RM5.84 TP.

If TauRX really could approved this year, we should keep or buy more. TP RM6.50 should not be a problem.

You still has the chance to buy low as same thing will happen again and again.

Maybank is the biggest seller and not buyer. Same style same announcement everytime when someone has push the price to lowest and accumulate at lowest price then asking Maybank to announce good news and sell at highest price. So many times.

https://theedgemalaysia.com/node/718932

KUALA LUMPUR (July 15): Maybank Investment Bank (IB) said it's the “last calls for bets” in a note on Monday for Genting Bhd (KL:GENTING), whose sum-of-parts (SOP)-based target price (TP) may be raised to RM9.35, if its 20%-owned TauRx Pharmaceuticals ends up getting valued at US$15 billion (RM70.11 billion).

The research house maintained its 'buy' rating for Genting, with an unchanged TP of RM5.84, despite the group's 'lacklustre' share price. At the time of writing on Monday, Genting shares had fallen two sen or 0.4% to RM4.56, valuing the group at RM17.7 billion.

Despite Maybank IB’s longrunning optimism, investors remained cautious on the prospects of TauRx especially after US Food and Drug Administration (FDA) in March delayed its decision on Eli Lilly’s Alzheimer’s drug experimental treatment for early Alzheimer's disease. The delay by the FDA was the second after the regulator declined to grant accelerated approval for the medicine a year ago.
Requests for "Fast Track" designation are made by drug companies, and the US FDA will review and decide on the request "based on whether the drug fills an unmet medical need in a serious condition", according to the regulator's website.

Genting's share price has eased 2% year-to-date, while the FBM KLCI has appreciated 11%.

Maybank believes this is unfounded, considering that Genting’s earnings have been recovering well to near pre-Covid levels, driven by the return of visitors to both 49%-owned Resorts World Genting and 53%-owned Resorts World Sentosa.

The house said Genting's share price weakness was the result of foreign selling, due to a weaker ringgit against the US dollar. It opined that the foreign selling is likely to taper.

“We notice that there is a strong correlation between Genting's discount to SOP/share and the MYR/USD.
“Our foreign exchange research team forecasts the USD/MYR to recover to 4.600 by end-2024, and 4.500 by mid-2025, from 4.718 as at June 30.

“We expect this to narrow Genting's valuation discount to SOP/share to 60% (as per the level in the financial year ended Dec 31, 2022), from 65% currently,” the house added.

On July 1, TauRx announced its submission of the UK marketing authorisation application for an experimental drug, hydromethylthionine mesylate (HMTM), for the treatment of mild cognitive impairment and mild to moderate stages of Alzheimer’s.

If HMTM is approved by year end, the research house expects the pharmaceutical company to be valued up to US$15 billion, achieving Maybank’s forecast TP for Genting.

Testing water. If still warm will go up after lunch.

Monday open above 4.60 and slowly all the way up to 4.70.

Nobody know Q2 2924 result.
If good can go back to 4.80.
If got good news 5.00

3 hours ago I already told you all it's time to buy.

I got a feeling they are testing the shorties before the next move.
Just hold back as the price already very low. Once they have collect enough. They will push the the price up and sell. They have been playing the same way many round.

it's time to buy.
Don't ask why. just feeling.

Can see light in the tunnel.

When shortists short enough and collect enough at lower price.
Shortists will push the price up again to 4.80 before Q2 2024 result announcement.

We need to teach the shorter a lesson.

Could it be Shorter selling down or some other reasons ?
Can we act together killing the shorter by buying up ?

Michaelchan2024.......what is you average purchase price ? still holding.

NTA RM8.98
PE 12.72
Dividend 3.22%
Why keep selling down when company is making more profit and increase in revenue ?
Are you all selling at a loss or profit ?

Let us pray and hope for the best.

Since already got some projects announcement. So just wait until it's finalize.
Hopefully some project could achieve before year end.

Stampid54.....sure boh ?

that Thestar.com news is for ELI Lilly.

https://www.thestar.com.my/news/world/2024/07/03/new-alzheimer039s-treatment-approved-by-us-fda

New Alzheimer's treatment approved by U.S. FDA

Very disappointed.
Imaging if UK could approve TauRX this year, share price shouldn't have problem breaking RM5.
Why still got so many sellers ?

why so many people willing to sell at this time ?
Are they making profit or selling at a loss ?

I hope tomorrow will go up with this latest news on TauRX.

When US LA casino IPO listing could happen? This year?

Why so many people selling down ?

Once US listing approved, breaking RM5 should not be a problem.

Forget about the fire. Problem solved. Small issues.
waiting for US IPO and TauRX. Positive outlook.

TauRX still no estimate time frame ?

A lot of people still have no confidence in EV car in Malaysia. Charging may be a big issues. Peruduo also coming up with local EV car which is a lot cheaper. It will take a least 3 years to get people confident

Did AGM update about TauRX status?

RWLV to be listed? really? When? Can reduce bank loans.
l

If LGT still around he will be ashamed of LKT. Useless CEO useless son.

When is Genting Singapore AGM ?

Ask TauRX status, when can get approval?

Pinky,t
Just now 15.27pm big volume throwing down at at 4.69 and 4.68.
Then 15.33 pm another big buyer accumulating at 4.69 and 4.70.
Buyer can wait slowly accumulate but seller cannot pick up forcing to sell down.
So far 4.70 very good support.
Once investors have accumulate enough, they will push higher.